6,7-Dihydro-2-methyl-5H-pyrinden | 25536-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6,7-Dihydro-2-methyl-5H-pyrinden
• 英文别名: methyl-2 cyclopentanopyridine；2-methyl-5,6,7-trihydrocyclopentapyridine；2-Methyl-6,7-dihydro-5H-[1]pyrindin；2-Methyl-6,7-dihydro-pyrindin；6-Methyl-2,3-pyrido-Δ^4'-cyclopenten；2-methyl-6,7-dihydro-5H-[1]pyrindine；2,3-Cyclopentano-6-methyl-pyridin；6-Methyl-2,3-cyclopentenpyridin；6,7-Dihydro-2-methyl-5H-1-pyrindine；2-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine
• CAS: 25536-14-5
• 化学式: C₉H₁₁N
• 分子量: 133.193
• InChiKey: HOAJAZVXWNQMOV-UHFFFAOYSA-N

物化性质

• 熔点：
  35.0-35.7 °C
• 沸点：
  211.9 °C(Press: 761 Torr)
• 密度：
  0.9910 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  methyl-6 (pentyn-4'-yl)-2 pyrimidone-4 以53%的产率得到
  参考文献：
  名称：

  ROUGEOT, E.;MOSKOWITZ, H.;MIOCQUE, M., J. HETEROCYCL. CHEM., 1983, 20, N 5, 1407-1409

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190315766A1

  公开（公告）日：2019-10-17

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物，以及其药学上可接受的盐、酯或前药： 这些化合物抑制呼吸道合胞病毒（RSV）。本发明还涉及包含上述化合物的药物组合物，用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Seiwert Scott D.

  公开号：US20090269305A1

  公开（公告）日：2009-10-29

  The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I、II、III、IV、V、VI、VII和X的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• A Ruthenium Catalyst with Unprecedented Effectiveness for the Coupling Cyclization of γ-Amino Alcohols and Secondary Alcohols
  作者：Bing Pan、Bo Liu、Erlin Yue、Qingbin Liu、Xinzheng Yang、Zheng Wang、Wen-Hua Sun

  DOI：10.1021/acscatal.5b02638

  日期：2016.2.5

  linyl)(carbonyl)(hydrido)ruthenium chloride exhibited extremely high efficiency toward the coupling cyclization of γ-amino alcohols with secondary alcohols. The corresponding products, pyridine or quinoline derivatives, are obtained in good to high isolated yields. On comparison with literature catalysts whose noble-metal loading with respect to γ-amino alcohols reached 0.5–1.0 mol % for Ru and a record

  钌络合物（8-（2-二苯基膦乙基）氨基三氢喹啉基）（羰基）（氢化）钌氯化物对γ-氨基醇与仲醇的偶联环化表现出极高的效率。以良好的分离产率或高的分离产率获得了相应的产物吡啶或喹啉衍生物。与文献中的催化剂相比，Ru的贵金属对γ-氨基醇的载量达到0.5-1.0 mol％，Ir达到创纪录的最低0.04 mol％，目前的催化剂在载量为0.025 mol％时达到了相同的效率。为茹。在DFT计算的基础上，提出了无受体脱氢缩合反应（ADC）的机理。另外，反应性中间体通过GC-MS，NMR和单晶X射线衍射测定。
• Synthesis of Pyridines and Pyrazines Using an Intramolecular Hydroamination-Based Reaction Sequence
  作者：Toni Rizk、Eric J.-F. Bilodeau、André M. Beauchemin

  DOI：10.1002/anie.200903922

  日期：2009.10.19

  A management issue! Various pyridines and pyrazines can be efficiently accessed from simple acyclic precursors using an intramolecular hydroamination/isomerization/aromatization sequence (see scheme). p‐Toluenesulfonic acid (2 mol %) is used to catalyze this novel alkyne annulation, in which the oxime group allows for a subsequent redox‐neutral aromatization step to occur.

  管理问题！可以使用分子内加氢胺化/异构化/芳构化序列（参见方案）从简单的无环前体有效地获得各种吡啶和吡嗪。对甲苯磺酸（2摩尔％）用于催化这种新型炔烃环化反应，其中肟基允许随后的氧化还原中性芳构化步骤发生。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。